Protagonist Therapeutics (PTGX) Stock Analysis & AI Equity Report
Protagonist Therapeutics (PTGX) overview
Protagonist Therapeutics (PTGX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 46.0m and operating profit of USD -158m; the year-end share price was 87.34 USD and market capitalisation was USD 5,466m. Protagonist Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Protagonist Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Protagonist Therapeutics
Protagonist Therapeutics discovers and develops peptide medicines for inflammatory, immunologic, hematologic, and metabolic diseases. Its partnered products include ICOTYDE (icotrokinra), an approved oral IL-23 receptor antagonist for plaque psoriasis commercialized by Johnson & Johnson, and MIMRYLO (rusfertide), approved for erythrocytosis in adults with polycythemia vera and commercialized by Takeda. The company also advances wholly owned peptide drug candidates.
Generate the Protagonist Therapeutics report
Protagonist Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Protagonist Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Protagonist Therapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.